| Studie | Medikament | Endpunkt | Veränderung des Triglycerid- und Cholesterin-Spiegels | Cardiovasculäres Risiko |
|
| Statin plus Placebo or Other Comparator | Statin plus Active Drug | ||||
| ACCORD Lipid(1) | Simvastatin plus fenofibrate vs. simvastatin | Kardiovaskulärer Herztod,überlebter Herzinfarkt, überlebter Apoplex | Triglycerides, -9%; HDL-C, +6%; LDL-C, -21% | Triglycerides, -22%; HDL-C, +8%; LDL-C, -19% | Hazard ratio, 0.92; 95% CI, 0.79– 1.08; P = 0.32 |
| AIM-HIGH(2) | Simvastatin plus niacin vs. simvastatin | Kardiovaskulärer Herztod,überlebter Herzinfarkt, überlebter Apoplex, akutes Coronarsyndrom, Revaskularisierung | Triglycerides, -8%; HDL-C, +10%; LDL-C, -6% | Triglycerides, -29%; HDL-C, +25%; LDL-C, -12% | Hazard ratio, 1.02; 95% CI, 0.87– 1.21; P = 0.80 |
| HPS2-THRIVE | Simvastatin with or without ezetimibe vs. simvastatin plus niacin and laropiprant | Kardiovaskulärer Herztod,überlebter Herzinfarkt, überlebter Apoplex, Revaskularisierung | NA | Triglycerides, -33 mg/dl (-0.37 mmol/liter); HDL-C, +6 mg/dl (+0.16 mmol/liter); LDL-C, -10 mg/dl (-0.28 mmol/liter) | Relative risk, 0.96; 95% CI, 0.90– 1.03; P = 0.29 |
| JELIS(3) | EPA plus statin vs. EPA | Kardiovaskulärer Herztod, überlebter Herzinfarkt, instabile Angina, Revaskularisierung | Triglycerides, -4%; HDL-C, +4%; LDL-C, -25% | Triglycerides, -9%; HDL-C, +3%; LDL-C, -25% | Hazard ratio, 0.81; 95% CI, 0.69– 0.95; P = 0.01 |
| ILLUMINATE(4) | Torcetrapib plus atorvastatin vs. atorvastatin | Kardiovaskulärer Herztod,überlebter Herzinfarkt, überlebter Apoplex, akutes Coronarsyndrom | Triglycerides, +1%; HDL-C, +2%; LDL-C, +3% | Triglycerides, -9%; HDL-C, +72%; LDL-C, -25% | Hazard ratio, 1.25; 95% CI, 1.14– 2.19; P = 0.006 |
| Dal-OUTCOMES(5) | Dalcetrapib plus statin vs. statin | Kardiovaskulärer Herztod,überlebter Herzinfarkt, überlebter Apoplex, instabile Angina, | Triglycerides, +17%; HDL-C, +11% | Triglycerides, +10%; HDL-C, +40% | Hazard ratio, 1.04; 95% CI, 0.93–1,16, p=0,52 |
Effects of combination lipid therapy in type 2 diabetes mellitus.
N Engl J Med 362(2010):1563-74
2. The AIM-HIGH Investigators:
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
N Engl J Med 365(2011):2255-67
3. Yokoyama M, Origasa H, Matsuzaki M, et al.:
Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients ( JELIS): a randomised open-label, blinded endpoint analysis.
Lancet 369(2007):1090-8
4. Barter PJ, Caulfield M, Eriksson M, et al.:
Effects of torcetrapib in patients at high risk for coronary events.
N Engl J Med 357(2007):2109-22
5. Schwartz GG, Olsson AG, Abt M, et al.:
Effects of dalcetrapib in patients with a recent acute coronary syndrome.
N Engl J Med 367(2012):2089-99
